References

nid

Нефрология и диализ

Nephrology and Dialysis

1680-44222618-9801

Российское диализное общество

10.28996/2618-9801-2025-2-116-166

nid-3833

Research Article

Статьи

Проект инициативных клинических рекомендаций по диагностике и лечению поражения почек при АНЦА-ассоциированных васкулитах

Clinical recommendations on diagnostics and treatment of kidney involvement in ANCA-associated vasculitis (Draft project)

https://orcid.org/0000-0002-3989-2590

Буланов

Н. М.

Bulanov

N. M.

Буланов Николай Михайлович – к.м.н., доцент кафедры внутренних, профессиональных болезней и ревматологии Института клинической медицины им. Н.В. Склифосовского

Москва, 119048, ул. Трубецкая, д. 8, стр. 2

Bulanov Nikolay Mikhailovich

8/2 Trubetskaya str., 119048, Moscow

nmbulanov@gmail.com

https://orcid.org/0000-0003-0178-7549

Захарова

Е. В.

Zakharova

E. V.

Захарова Елена Викторовна – к.м.н., заведующая нефрологическим отделением;

доцент кафедры нефрологии ФПДО;

доцент кафедры нефрологии и гемодиализа

125284, Москва, 2-й Боткинский проезд, 5;

125993, Москва, ул. Баррикадная, 2/1 стр. 1;

127006, Москва, ул. Долгоруковская, 4

Zakharova Elena Viktorovna

5, 2nd Botkinsky drive, 125284, Moscow;

2/1 bld, 1, Barrikadnaya str, 125993, Moscow;

4, Dolgorukovskaya str., 12700, Moscow

helena.zakharova@gmail.com

https://orcid.org/0000-0002-4275-0315

Козловская

Н. Л.

Kozlovskaya

N. L.

Козловская Наталья Львовна – д.м.н., проф., руководитель центра помощи беременным с патологией почек и мочевыводящих путей;

профессор кафедры внутренних болезней с курсами кардиологии и функциональной диагностики им. академика В.С. Моисеева

129327, Москва, ул. Ленская, 15;

117198, Москва, ул. Миклухо-Маклая, 6

Kozlovskaya Natalia Lvovna

15, Lenskaya str., 129327, Moscow;

6, Miklukho-Maklaya str., 117198, Moscow

nkozlovskaya@yandex.ru

https://orcid.org/0000-0001-8497-0693

Ватазин

А. В.

Vatazin

A. V.

Ватазин Андре Владимирович – д.м.н., проф., руководитель хирургического отделения трансплантации почки, зав. кафедрой трансплантологии, нефрологии и искусственных органов;

Главный внештатный специалист нефролог Минздрава РФ по ЦФО

129110, Москва, ул. Щепкина, д. 61/23

Vatazin Andrey Vladimirovich

61/23, Shchepkin str., 129110, Moscow

vatazin@yandex.ru

https://orcid.org/0000-0003-0758-8137

Карунная

А. В.

Karunnaya

A. V.

Карунная Анна Викторовна (секретарь рабочей группы) – врач-нефролог отделения хронического гемодиализа клиники научно-исследовательского института нефрологии

197022, Санкт-Петербург, ул. Льва Толстого, 6-8

Karunnaya Anna Viktorovna

6-8, Lev Tolstoy str., 197022, Saint Petersburg

a.v.karunnaya@yandex.ru

https://orcid.org/0000-0002-7179-5520

Добронравов

В. А.

Dobronravov

V. A.

Добронравов Владимир Александрович (председатель рабочей группы) – д.м.н., профессор, директор научно-исследовательского института нефрологии, профессор кафедр пропедевтики внутренних болезней с клиникой и нефрологии и диализа

197022, Санкт-Петербург, ул. Льва Толстого, 6-8

Dobronravov Vladimir Alexandrovich

6-8, Lev Tolstoy str., 197022, Saint Petersburg

dobronravov@nephrolog.ru

ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава РоссииРоссияSechenov First Moscow State Medical UniversityRussian Federation

ГБУЗ ММНКЦ «Боткинская больница» ДЗМ; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России; ФГБОУ ВО «Российский университет медицины» Минздрава РоссииРоссияMoscow Scientific Clinical Center “Botkin Hospital”; Russian Medical Academy of Continuing Professional Education; Russian University of MedicineRussian Federation

ГБУЗ «ГКБ им. А.К. Ерамишанцева» ДЗМ; ФГАОУ ВО «Российский университет дружбы народов им. Патриса Лумумбы»РоссияA.K. Eramishantsev City Hospital; RUDN UniversityRussian Federation

ГБУЗ МО «Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского»РоссияMoscow Regional Research and Clinical InstituteRussian Federation

ФГБОУ ВО «Первый СПб ГМУ им. акад. И.П. Павлова» Минздрава РоссииРоссияPavlov First Saint Petersburg State Medical UniversityRussian Federation

2025

15072025

272116166

2025

Буланов Н.М., Захарова Е.В., Козловская Н.Л., Ватазин А.В., Карунная А.В., Добронравов В.А.

Bulanov N.M., Zakharova E.V., Kozlovskaya N.L., Vatazin A.V., Karunnaya A.V., Dobronravov V.A.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://journal.nephro.ru/jour/article/view/3833

References1

Jennette JC, Falk RJ, Bacon PA et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1-11. doi:10.1002/art.37715

Lyons PA, Rayner TF, Trivedi S et al. Genetically Distinct Subsets within ANCA-Associated Vasculitis. New England Journal of Medicine. 2012;367(3):214-223. doi:10.1056/NEJMoa1108735

Xie G, Roshandel D, Sherva R et al. Association of granulomatosis with polyangiitis (Wegener’s) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis. Arthritis Rheum. 2013;65(9):2457-2468. doi:10.1002/art.38036

Tadema H, Abdulahad WH, Lepse N et al. Bacterial DNA motifs trigger ANCA production in ANCA-associated vasculitis in remission. Rheumatology (Oxford). 2011;50(4):689-696. doi:10.1093/rheumatology/keq375

Bienaimé F, Clerbaux G, Plaisier E et al. d-Penicillamine-Induced ANCA-Associated Crescentic Glomerulonephritis in Wilson Disease. American Journal of Kidney Diseases. 2007;50(5):821-825. doi:10.1053/j.ajkd.2007.05.026

Bienaimé F, Clerbaux G, Plaisier E et al. d-PenicillamineInduced ANCA-Associated Crescentic Glomerulonephritis in Wilson Disease. American Journal of Kidney Diseases. 2007;50(5):821-825. doi:10.1053/j.ajkd.2007.05.026

Nolan AL, Jen KY. Pathologic manifestations of levamisole-adulterated cocaine exposure. Diagn Pathol. 2015;10(1). doi:10.1186/s13000-015-0279-z

Gómez-Puerta JA, Gedmintas L, Costenbader KH. The association between silica exposure and development of ANCA-associated vasculitis: systematic review and meta-analysis. Autoimmun Rev. 2013;12(12):1129-1135. doi:10.1016/j.autrev.2013.06.016

Xiao H, Heeringa P, Hu P et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest. 2002;110(7):955-963. doi:10.1172/JCI15918

Little MA, Al-Ani B, Ren S et al. Anti-proteinase 3 anti-neutrophil cytoplasm autoantibodies recapitulate systemic vasculitis in mice with a humanized immune system. PLoS One. 2012;7(1):e28626. doi:10.1371/journal.pone.0028626

Schlieben DJ, Korbet SM, Kimura RE et al. Pulmonaryrenal syndrome in a newborn with placental transmission of ANCAs. American Journal of Kidney Diseases. 2005;45(4):758-761. doi:10.1053/j.ajkd.2005.01.001

Kemna MJ, Damoiseaux J, Austen J et al. ANCA as a predictor of relapse: Useful in patients with renal involvement but not in patients with nonrenal disease. Journal of the American Society of Nephrology. 2015;26(3):537-542. doi:10.1681/ASN.2013111233

Muller Kobold AC, van der Geld YM, Limburg PC et al. Pathophysiology of ANCA-associated glomerulonephritis. Nephrol Dial Transplant. 1999;14(6):1366-1375. doi: 10.1093/ndt/14.6.1366

Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A. 1990;87(11):4115-4119.

Radford DJ, Luu NT, Hewins P et al. Antineutrophil cytoplasmic antibodies stabilize adhesion and promote migration of flowing neutrophils on endothelial cells. Arthritis Rheum. 2001;44(12):2851-2861. doi: 10.1002/1529-0131(200112)44:12<2851::aid-art473>3.0.co;2-2

Kessenbrock K, Krumbholz M, Schönermarck U et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med. 2009;15(6):623-625. doi:10.1038/nm.1959

Hilhorst M, Paassen P Van, Rie H Van et al. Complement in ANCA-associated glomerulonephritis. Nephrol Dial Transplant. 2015;32(8):1302-1313. doi:10.1093/ndt/gfv288

Gou SJ, Yuan J, Chen M et al. Circulating complement activation in patients with anti-neutrophil cytoplasmic antibodyassociated vasculitis. Kidney Int. 2013;83(1):129-137. doi:10.1038/ki.2012.313

Gou SJ, Yuan J, Wang C et al. Alternative complement pathway activation products in urine and kidneys of patients with ANCA-associated GN. Clinical Journal of the American Society of Nephrology. 2013;8(11):1884-1891. doi:10.2215/CJN.02790313

Jayne DRW, Bruchfeld AN, Harper L et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. Journal of the American Society of Nephrology. 2017;28(9):2756-2767. doi:10.1681/ASN.2016111179

Hruskova Z, Rihova Z, Mareckova H et al. Intracellular cytokine production in ANCA-associated vasculitis: low levels of interleukin-10 in remission are associated with a higher relapse rate in the long-term follow-up. Arch Med Res. 2009;40(4):276-284. doi:10.1016/j.arcmed.2009.04.001

Lamprecht P, Wieczorek S, Epplen JT et al. Granuloma formation in ANCA-associated vasculitides. APMIS Suppl. 2009;(127):32-36. doi:10.1111/j.1600-0463.2009.02474.x

Watts RA, Mahr A, Mohammad AJ et al. Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Nephrol Dial Transplant. 2015;30(Suppl1):i14-22. doi:10.1093/ndt/gfv022

Berti A, Cornec-Le Gall E, Cornec D et al. Incidence, prevalence, mortality and chronic renal damage of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in a 20-year population-based cohort. Nephrology Dialysis Transplantation. 2019;34(9):1508-1517. doi:10.1093/ndt/gfy250

Новиков ПИ, Моисеев СВ, Кузнецова ЕИ и соавт. Изменение клинического течения и прогноза гранулематоза с полиангиитом (Вегенера): результаты 40-летнего наблюдения. Клиническая фармакология и терапия. 2014;23(1):32-37.

Novikov PI, Moiseev SV, Kuznetsova EI et al. Changing patterns of clinical severity and risk of mortality in granulomatosis with polyangiitis over four decades. Clin Pharmacol Ther. 2014;23(1):32-37.] (In Russian)

Томилина НА, Бирюкова ЛС, Фролова и соавт. Клинико-морфологическая характеристика и прогноз разных гистоморфологических вариантов быстропрогрессирующего гломерулонефрита, ассоциированного с АНЦА-васкулитом. Нефрология и диализ. 2017;19(4):466-477. doi:10.28996/1680-4422-2017-4-466-477

Tomilina NA, Biryukova LS, Frolova NF et al. Clinical and morphological characteristics and prognosis of different histomorphological variants of rapidly progressing glomerulonephritis associated with ANCA-vasculitis. Nephrology and Dialysis. 2017;19(4):466-477.] doi:10.28996/1680-4422-2017-4-466-477 (In Russian)

Mohammad AJ, Jacobsson LTH, Westman KWA et al. Incidence and survival rates in Wegener’s granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. Rheumatology. 2009;48(12):1560-1565. doi:10.1093/rheumatology/kep304

cr.minzdrav.gov.ru [Internet]. Kлинические рекомендации. Хроническая болезнь почек, 2024. Доступно по ссылке: https://cr.minzdrav.gov.ru/view-cr/469_3. Дата обращения 14 июня 2025.

cr.minzdrav.gov.ru [Internet]. Clinical guidelines. Chronic kidney disease, 2024. Available at: https://cr.minzdrav.gov.ru/view-cr/469_3.] Accessed June 14, 2025 (In Russian)

Kallenberg CGM. Pathogenesis of ANCA-associated vasculitides. Ann Rheum Dis. 2011;70(Suppl 1):i59-i63. doi:10.1136/ard.2010.138024

Novikov P, Smitienko I, Bulanov N et al. Testing for antineutrophil cytoplasmic antibodies (ANCAs) in patients with systemic vasculitides and other diseases. Ann Rheum Dis. 2016;76(8):e23. doi:10.1136/annrheumdis-2016-210890

Jennette JC, Wilkman AS, Falk RJ. Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis. Am J Pathol. 1989;135(5):921-930.

Bosch X, Mirapeix E, Font J et al. Anti-myeloperoxidase autoantibodies in patients with necrotizing glomerular and alveolar capillaritis. Am J Kidney Dis. 1992;20(3):231-239. doi: 10.1016/s0272-6386(12)80695-0

Holle JU, Laudien M, Gross WL. Clinical Manifestations and Treatment of Wegener’s Granulomatosis. Rheumatic Disease Clinics of North America. 2010;36(3):507-526. doi:10.1016/j.rdc.2010.05.008

Villiger PM, Guillevin L. Microscopic polyangiitis: Clinical presentation. Autoimmun Rev. 2010;9(12):812-819. doi:10.1016/j.autrev.2010.07.009

Щеголева ЕМ, Буланов НМ, Новиков ПИ, Моисеев СВ. Клинические особенности поражения почек при микроскопическом полиангиите. Терапевтический архив. 2018; 90(6):55-58. doi: 10.26442/terarkh201890655-58

Shchegoleva EM, Bulanov NM, Novikov PI, Moiseev SV. Clinical features of kidney involvement in microscopic polyangiitis. Terapevticheskii arkhiv. 2018;90(6):55-58.] doi: 10.26442/terarkh201890655-58 (In Russian)

Guillevin L, Cohen P, Gayraud M et al. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine. 1999;78(1):26-37.

Буланов НМ, Моисеев СВ, Новиков ПИ и соавт. Поражение почек при различных вариантах АНЦА-ассоциированного васкулита. Клиническая фармакология и терапия. 2016;25(5):23-29. doi: 10.1097/00005792-199901000-00003

Bulanov NM, Moiseev SV, Novikov PI et al. Renal involvement in ANCA-associated vasculitis. Clin Pharmacol Ther. 2016;25(5):23-29.] doi: 10.1097/00005792-199901000-00003 (In Russian)

Leavitt RY, Fauci AS, Bloch DA et al. The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum. 1990;33(8):1101-1107. doi:10.1002/ART.1780330807

Masi AT, Hunder GG, Lie JT et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33(8):1094-1100. doi:10.1002/art.1780330806

Masi AT, Hunder GG, Lie JT et al. The American College of Rheumatology 1990 criteria for the classification of ChurgStrauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33(8):1094-1100. doi:10.1002/art.1780330806

Seeliger B, Sznajd J, Robson JC et al. Are the 1990 American College of Rheumatology vasculitis classification criteria still valid? Rheumatology (United Kingdom). 2017;56(7):1154-1161. doi:10.1093/rheumatology/kex075

Robson JC, Grayson PC, Ponte C et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. Ann Rheum Dis. 2022;81(3):315-320. doi:10.1136/ANNRHEUMDIS-2021-221795

Suppiah R, Robson JC, Grayson PC et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. Ann Rheum Dis. 2022;81(3):321-326. doi:10.1136/ANNRHEUMDIS-2021-221796

Grayson PC, Ponte C, Suppiah R et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis. Ann Rheum Dis. 2022;81(3):309-314. doi:10.1136/ANNRHEUMDIS-2021-221794

Mukhtyar C, Guillevin L, Cid MC et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009;68(3):310-317. doi:10.1136/ard.2008.088096

Jennette JC. Rapidly progressive crescentic glomerulonephritis. Kidney Int. 2003;63(3):1164-1177. doi:10.1046/j.1523-1755.2003.00843.x

Falk RJ, Moore DT, Hogan SL, Jennette JC. A renal biopsy in essential for the management of ANCA-positive patients with glomerulonephritis. Sarcoidosis Vasc Diffuse Lung Dis. 1996;13(3):230-231.

rusnephrology.org [Internet]. Клинические рекомендации. Острое повреждение почек. Доступно по ссылке: https://rusnephrology.org/wp-content/uploads/2020/12/AKI_final.pdf. Дата обращения 14 июня 2025.

rusnephrology.org [Internet]. Clinical guidelines. Acute kidney injury. Available at: https://rusnephrology.org/wp-content/uploads/2020/12/AKI_final.pdf.] Accessed June 14, 2025 (In Russian)

Yu A, Chertow G, Luyckx V et al. Brenner and Rector’s The Kidney, 11th Ed. Publisher Elsevier. 2019. ISBN: 9780323532655

Deshayes S, Aouba A, Khoy K et al. Hypocomplementemia is associated with worse renal survival in anca-positive granulomatosis with polyangiitis and microscopic polyangiitis. PLoS One. 2018;13(4). doi:10.1371/journal.pone.0195680

Augusto JF, Langs V, Demiselle J et al. Low serum complement C3 levels at diagnosis of renal ANCA-associated vasculitis is associated with poor prognosis. PLoS One. 2016;11(7). doi:10.1371/journal.pone.0158871

Crnogorac M, Horvatic I, Kacinari P et al. Serum C3 complement levels in ANCA associated vasculitis at diagnosis is a predictor of patient and renal outcome. J Nephrol. 2018;31(2):257-262. doi:10.1007/s40620-017-0445-3

Guchelaar NAD, Waling MM, Adhin AA et al. The value of anti-neutrophil cytoplasmic antibodies (ANCA) testing for the diagnosis of ANCA-associated vasculitis, a systematic review and meta-analysis. Autoimmun Rev. 2021;20(1):102716. doi:10.1016/j.autrev.2020.102716

Bossuyt X, Cohen Tervaert JW, Arimura Y et al. Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheumatol. 2017;13(11):683-692. doi:10.1038/nrrheum.2017.140

Damoiseaux J, Csernok E, Rasmussen N et al. Detection of antineutrophil cytoplasmic antibodies (ANCAs): a multicentre European Vasculitis Study Group (EUVAS) evaluation of the value of indirect immunofluorescence (IIF) versus antigenspecific immunoassays. Ann Rheum Dis. 2017;76(4):647-653. doi:10.1136/annrheumdis-2016-209507

Savige J, Dimech W, Fritzler M et al. Addendum to the International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies: Quality Control Guidelines, Comments, and Recommendations for Testing in Other Autoimmune Diseases. Am J Clin Pathol. 2003;120(3):312-318. doi:10.1309/waep-adw0-k4lp-uhfn

Csernok E, Damoiseaux J, Rasmussen N et al. Evaluation of automated multi-parametric indirect immunofluorescence assays to detect anti-neutrophil cytoplasmic antibodies (ANCA) in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Autoimmun Rev. 2016;15(7):736-741. doi:10.1016/j.autrev.2016.03.010

Shah S, Hruskova Z, Segelmark M et al. Treatment of severe renal disease in ANCA positive and negative small vessel vasculitis with rituximab. Am J Nephrol. 2015;41(4-5):296-301. doi:10.1159/000431336

Wester Trejo MAC, Floßmann O, Westman KW et al. Renal relapse in antineutrophil cytoplasmic autoantibody-associated vasculitis: unpredictable, but predictive of renal outcome. Rheumatology (Oxford). 2019;58(1):103-109. doi: 10.1093/rheumatology/key260

Chakravarty K, McDonald H, Pullar T et al. BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. Rheumatology. 2008;47(6):924-925. doi:10.1093/rheumatology/kel216a

Jayne D, Rasmussen N, Andrassy K et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349(1):36-44. doi:10.1056/NEJMoa020286

Talar-Williams C, Hijazi YM, Walther MM et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med. 1996;124(5):477-484. doi:10.7326/0003-4819-124-5-199603010-00003

Knight A, Askling J, Granath F et al. Urinary bladder cancer in Wegener’s granulomatosis: Risks and relation to cyclophosphamide. Ann Rheum Dis. 2004;63(10):1307-1311. doi:10.1136/ard.2003.019125

Stillwell TJ, Benson RC, Deremee RA et al. Cyclophosphamide-induced bladder toxicity in wegener’s granulomatosis. Arthritis Rheum. 1988;31(4):465-470. doi:10.1002/art.1780310402

Suppiah R, Mukhtyar C, Flossmann O et al. A crosssectional study of the Birmingham vasculitis activity score version 3 in systemic vasculitis. Rheumatology. 2011;50(5):899-905. doi:10.1093/rheumatology/keq400

Exley AR, Bacon PA, Luqmani RA et al. Development and initial validation of the vasculitis damage index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum. 1997;40(2):371-380. doi:10.1002/art.1780400222

Tomasson G, Grayson PC, Mahr AD et al. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis-a meta-analysis. Rheumatology. 2012;51(1):100-109. doi:10.1093/rheumatology/ker280

Al-Soudi A, Vegting Y, Klarenbeek PL, Hilhorst ML. Do Relapses Follow ANCA Rises? A Systematic Review and Meta-Analysis on the Value of Serial ANCA Level Evaluation. Front Med (Lausanne). 2022;9. doi:10.3389/FMED.2022.844112,

Al-Soudi A, Vegting Y, Klarenbeek PL, Hilhorst ML. Do Relapses Follow ANCA Rises? A Systematic Review and MetaAnalysis on the Value of Serial ANCA Level Evaluation. Front Med (Lausanne). 2022;9. doi:10.3389/FMED.2022.844112,

Mehta P, Balakrishnan A, Phatak S et al. Diagnostic accuracy of antineutrophil cytoplasmic antibodies (ANCA) in predicting relapses of ANCA-associated vasculitis: systematic review and meta-analysis. Rheumatol Int. 2023;43(3):437-448. doi:10.1007/S00296-022-05192-3,

Finkielman JD, Merkel PA, Schroeder D et al. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med. 2007;147(9):611-619.

Boomsma MM, Stegeman CA, van der Leij MJ et al. Prediction of relapses in Wegener’s granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum. 2000;43(9):2025-2033. doi:10.1002/1529-0131(200009)43:9<2025::AID-ANR13>3.0.CO;2-O

Venhoff N, Effelsberg NM, Salzer U et al. Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCAassociated vasculitides. PLoS One. 2012;7(5):e37626. doi:10.1371/journal.pone.0037626

Marco H, Smith RM, Jones RB et al. The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease. BMC Musculoskelet Disord. 2014;15(1):178. doi:10.1186/1471-2474-15-178

Feragalli B, Mantini C, Sperandeo M et al. The lung in systemic vasculitis: Radiological patterns and differential diagnosis. British Journal of Radiology. 2016;89(1061):20150992. doi:10.1259/bjr.20150992

Zhou P, Ma J, Wang G. Impact of interstitial lung disease on mortality in ANCA-associated vasculitis: A systematic literature review and meta-analysis. Chron Respir Dis. 2021;15(8):1103-1111. doi:10.1177/1479973121994562

Huang S, Shen Q, Yang R et al. An evaluation of the 2010 histopathological classification of anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis: a Bayesian network meta-analysis. Int Urol Nephrol. 2018;50(10):1853-1861. doi:10.1007/s11255-018-1941-7

van Daalen EE, Wester Trejo MAC, Göçeroglu A et al. Developments in the histopathological classification of ANCAassociated glomerulonephritis. Clinical Journal of the American Society of Nephrology. 2020;15(8):1103-1111. doi:10.2215/CJN.14561119

Xia M, Yu R, Zheng Z et al. Meta-Analytical Accuracy of ANCA Renal Risk Score for Prediction of Renal Outcome in Patients With ANCA-Associated Glomerulonephritis. Front Med (Lausanne). 2022;8: 736754. doi:10.3389/FMED.2021.736754,

Aasarød K, Bostad L, Hammerstrøm J et al. Renal histopathology and clinical course in 94 patients with Wegener’s granulomatosis. Nephrology Dialysis Transplantation. 2001;16(5):953-960. doi:10.1093/ndt/16.5.953

Schnabel A, Holl-Ulrich K, Dalhoff et al. Efficacy of transbronchial biopsy in pulmonary vaculitides. European Respiratory Journal. 1997;10(12):2738-2743. doi:10.1183/09031936.97.10122738

Devaney KO, Travis WD, Hoffman G et al. Interpretation of head and neck biopsies in Wegener’s granulomatosis. A pathologic study of 126 biopsies in 70 patients. American Journal of Surgical Pathology. 1990;14(6):555-564. doi:10.1097/00000478-199006000-00006

Prasad N, Kumar S, Manjunath R et al. Real-time ultrasound-guided percutaneous renal biopsy with needle guide by nephrologists decreases post-biopsy complications. Clin Kidney J. 2015;8(2):151-156. doi:10.1093/ckj/sfv012

Berden AE, Ferrario F, Hagen EC et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol. 2010;21(10):1628-1636. doi:10.1681/ASN.2010050477

Brix SR, Noriega M, Tennstedt P et al. Development and validation of a renal risk score in ANCA-associated glomerulonephritis. Kidney Int. 2018;94(6):1177-1188. doi:10.1016/j.kint.2018.07.020

Gercik O, Bilgin E, Solmaz D. Histopathological subgrouping versus renal risk score for the prediction of end-stage renal disease in ANCA-associated vasculitis. 2020;79(5):675-676. doi:10.1136/annrheumdis-2019-216742

Bate S, McGovern D, Costigliolo F et al. The Improved Kidney Risk Score in ANCA-Associated Vasculitis for Clinical Practice and Trials. Journal of the American Society of Nephrology. 2024;35(3):335-346. doi:10.1681/ASN.0000000000000274

Буланов НМ, Тао ЕА, Столяревич ЕС и соавт. Сравнение инструментов оценки прогноза почечной выживаемости у пациентов с АНЦА-ассоциированным гломерулонефритом: ретроспективное когортное исследование. 2024;33(4):44-50.doi:10.32756/0869-5490-2024-4-44-50

Bulanov NM, Tao EA, Stoliarevich ES et al. Comparison of the different prediction tools for kidney survival in ANCA-associated glomerulonephritis: a retrospective cohort study. Clin Pharmacol Ther. 2024;33(4):44-50] doi:10.32756/0869-5490-2024-4-44-50 (In Russian)

Добронравов ВА, Карунная АВ, Казимирчик АВ, Смирнов АВ. АНЦА-ассоциированные васкулиты с домини рующим поражением почек: клинико-морфологическая презентация и исходы. Нефрология. 2019;23(6):29-44. doi:10.36485/1561-6274-2019-236-29-44

Dobronravov VA, Karunnaya AV., Kazimirchik AV, Smirnov AV. ANCA-associated vasculitis with dominant renal involvement: clinical and morphological presentation and outcomes. Nephrology (Saint-Petersburg). 2019;23(6):29-44.] doi:10.36485/1561-6274-2019-236-29-44 (In Russian)

Moosig F, Bremer JP, Hellmich B et al. A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): Monocentric experiences in 150 patients. Ann Rheum Dis. 2013;72(6):1011-1017. doi:10.1136/annrheumdis-2012-201531

Rovin BH, Adler SG, Barratt J et al. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4):S1-S276. doi:10.1016/j.kint.2021.05.021

Mukhtyar C, Lee R, Brown D et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2009;68(12):1827-1832. doi:10.1136/ard.2008.101279

Charlier C, Henegar C, Launay O et al. Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients. Ann Rheum Dis. 2009;68(5):658-663. doi:10.1136/ARD.2008.088302

Iudici M, Pagnoux C, Courvoisier DS et al. Granulomatosis with polyangiitis: Study of 795 patients from the French Vasculitis Study Group registry. Semin Arthritis Rheum. 2021;51(2):339-346. doi:10.1016/J.SEMARTHRIT.2021.02.002

Литвинова МА, Буланов НМ, Новиков ПИ и соавт. Коморбидные инфекции у пациентов с АНЦА-ассоциированными системными васкулитами: проспективное когортное исследование. Современная ревматология. 2025; 19(2):50-57.doi:10.14412/1996-7012-2025-2-50-57

Litvinova MA, Bulanov NM, Novikov PI et al. Comorbid infections in patients with ANCA-associated systemic vasculitis: a prospective cohort study. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2025;19(2):50-57.] doi:10.14412/1996-7012-2025-2-50-57 (In Russian)

Luo W, Liu C, Zhang L et al. Characteristics and risk factors for infection in patients with ANCA-associated vasculitis: A systematic review and meta-analysis. Autoimmun Rev. 2025;24(2): 103713. doi:10.1016/j.autrev.2024.103713

Leong A, Fong W. Factors associated with cytomegalovirus infection in antineutrophil cytoplasmic antibody-associated vasculitis: A narrative review. Int J Rheum Dis. 2022;25(12):1357-1367. doi:10.1111/1756-185X.14444

Kronbichler A, Jayne DRW, Mayer G. Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis. Eur J Clin Invest. 2015;45(3):346-368. doi:10.1111/ECI.12410

Baliga S, Yadav S, Sagdeo P, Balakrishnan C. Invasive fungal infection in ANCA-associated vasculitis: Between the Devil and Deep blue sea. Case series and review of the literature. Clin Rheumatol. 2024;43(2):785-797. doi:10.1007/S10067-023-06785-4

Thery-Casari C, Euvrard R, Mainbourg S et al. Severe infections in patients with anti-neutrophil cytoplasmic antibodyassociated vasculitides receiving rituximab: A meta-analysis. Autoimmun Rev. 2020;19(5):102505. doi:10.1016/j.autrev.2020.102505

Shang W, Ning Y, Xu X et al. Incidence of Cancer in ANCA-Associated Vasculitis: A Meta-Analysis of Observational Studies. PLoS One. 2015;10(5):e0126016. doi:10.1371/JOURNAL.PONE.0126016

Faurschou M, Sorensen IJ, Mellemkjaer L et al. Malignancies in Wegener’s granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol. 2008;35(1):100-105.

100

Houben E, Penne EL, Voskuyl AE et al. Cardiovascular events in anti-neutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis of observational studies. Rheumatology (United Kingdom). 2018;57(3):555-562. doi:10.1093/rheumatology/kex338

101

Lee JJ, Pope JE. A meta-analysis of the risk of venous thromboembolism in inflammatory rheumatic diseases. Arthritis Res Ther. 2014;16(5):435. doi:10.1186/s13075-014-0435-y

102

Goyal A, Abbasi HQ, Mashkoor Y et al. Assessment of cardiovascular risk in patients with ANCA-associated vasculitis: A systematic review and meta-analysis. International Journal of Cardiology: Cardiovascular Risk and Prevention. 2024;23:200334. doi:10.1016/j.ijcrp.2024.200334

103

Suppiah R, Judge A, Batra R et al. A model to predict cardiovascular events in patients with newly diagnosed Wegener’s granulomatosis and microscopic polyangiitis. Arthritis Care Res (Hoboken). 2011;63(4):588-596. doi:10.1002/acr.20433

104

Макаров ЕА, Новиков ПИ, Шевцова ТП и соавт. Венозные тромбоэмболические осложнения при АНЦАассоциированных васкулитах. Клиническая фармакология и терапия. 2017;26(3):37-42.

Makarov EA, Novikov PI, Shevtsova TP et al. Venous thromboembolic events in patients with ANCAassociated vasculitides. Clin Pharmacol Ther. 2017;26 (3):37-42.] (In Russian)

105

Moiseev S, Kronbichler A, Makarov E et al. Association of venous thromboembolic events with skin, pulmonary and kidney involvement in ANCA-associated vasculitis: a multinational study. Rheumatology. 2021;60(10):4654-4661. doi:10.1093/rheumatology/keab071

106

Moiseev S, Novikov P, Bulanov N et al. Cardiovascular risk assessment in patients with ANCA-associated vasculitis. Arthritis & Rheumatology. 2020;72(1):200-201. doi:10.1002/art.41080

107

Кузнецова ЕИ, Моисеев СВ, Новиков ПИ и соавт. Субклинический атеросклероз периферических артерий у больных гранулематозом с полиангиитом (Вегенера). Клиническая фармакология и терапия. 2013;22(4):36-41.

Kuznetsova EI, Moiseev SV, Novikov PI et al. Subclinical atherosclerosis of peripheral arteries in patients with granulomatosis with polyangiitis (Wegener’s). Clin Pharmacol Ther. 2013;22(4):36-41.] (In Russian)

108

Wallace ZS, Fu X, Liao K et al. Disease activity, antineutrophil cytoplasmic antibody type, and lipid levels in antineutrophil cytoplasmic antibody–associated vasculitis. Arthritis Rheumatol. 2019;71(11):1879-1887. doi:10.1002/art.41006

109

Moiseev S, Bulanov N, Crnogorac M et al. Traditional and Disease-Specific Risk Factors for Cardiovascular Events in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Multinational Retrospective Study. Journal of Rheumatology. 2023;50(9):1145-1151. doi:10.3899/JRHEUM.220851,

110

Walton EW. Giant-cell granuloma of the respiratory tract (Wegener’s granulomatosis). Br Med J. 1958;2(5091):265-270.

111

de Groot K, Adu D, Savage CO et al. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant. 2001;16(10):2018-2027. doi:10.1093/ndt/16.10.2018

112

de Groot K, Harper L, Jayne DRW et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009;150(10):670-680. doi:10.7326/0003-4819-150-10-200905190-00004

113

Hoffman GS, Kerr GS, Leavitt RY et al. Wegener Granulomatosis: An Analysis of 158 Patients. Ann Intern Med. 1992;116(6):488. doi:10.7326/0003-4819-116-6-488

114

Novack SN, Pearson CM. Cyclophosphamide Therapy in Wegener’s Granulomatosis. New England Journal of Medicine. 1971;284(17):938-942. doi:10.1056/NEJM197104292841703

115

Ntatsaki E, Carruthers D, Chakravarty K et al. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (United Kingdom). 2014;53(12):2306-2309. doi:10.1093/rheumatology/ket445

116

Bender TTA, Leyens J, Sellin J et al. Therapeutic options for patients with rare rheumatic diseases: a systematic review and meta-analysis. Orphanet J Rare Dis. 2020;15(1):308. doi:10.1186/s13023-020-01576-5

117

Lee YH, Song GG. Comparative efficacy and safety of rituximab, mycophenolate, and cyclophosphamide in active antineutrophil cytoplasmic antibodyassociated vasculitis: A Bayesian network meta-analysis of randomized controlled trials. Int J Clin Pharmacol Ther. 2021;59(10):645-653. doi:10.5414/CP204024,

118

Jones RB, Tervaert JWC, Hauser T et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211-220. doi:10.1056/NEJMoa0909169

119

Stone JH, Merkel PA, Spiera R et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221-232. doi:10.1056/NEJMoa0909905

120

Caroti L, Cirami CL, Di Maria L et al. Rituximab in relapsing and de novo MPO ANCA-associated vasculitis with severe renal involvement: A case series. BMC Nephrol. 2019;20(1):162. doi:10.1186/s12882-019-1350-x

121

Walsh M, Merkel P, Peh C et al. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. N Engl J Med. 2020;382:622-631. doi:10.1056/NEJMoa1803537

122

Alchi MB, Lever R, Flossmann O, Jayne D. Efficacy and safety of low- versus high-dose glucocorticoid regimens for induction of remission of anti-neutrophil cytoplasm antibodyassociated vasculitis: a systematic review and meta-analysis. Scand J Rheumatol. 2023;52(5):564-573. doi:10.1080/03009742.2023.2211387,

123

Furuta S, Nakagomi D, Kobayashi Y et al. Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis: A Randomized Clinical Trial. JAMA. 2021;325(21):1-10. doi:10.1001/JAMA.2021.6615

124

Jayne DRW, Gaskin G, Rasmussen N et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007;18(7):2180-2188. doi:10.1681/ASN.2007010090

125

Yates M, Watts RA, Bajema IM et al. EULAR/ERAEDTA recommendations for the management of ANCAassociated vasculitis. Ann Rheum Dis. 2016;75(9):1583-1594. doi:10.1136/annrheumdis-2016-209133

126

Guillevin L, Pagnoux C, Karras A et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371(19):1771-1780. doi:10.1056/NEJMoa1404231

127

Chanouzas D, McGregor JAG, Nightingale P et al. Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated Vasculitis: A multi-center retrospective cohort study 11 Medical and Health Sciences 1103 Clinical Sciences. BMC Nephrol. 2019;20(1):58. doi:10.1186/s12882-019-1226-0

128

Jayne DRW, Merkel PA, Schall TJ, Bekker P. Avacopan for the Treatment of ANCA-Associated Vasculitis. N Engl J Med. 2021;384(7):599-609. doi:10.1056/NEJMOA2023386

129

Gattu R, Demory Beckler M, Kesselman MM. Superiority of Avacopan and Mepolizumab to Glucocorticoid Tapering in the Treatment of Anti-neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis: A Systematic Review. Cureus. 2024;16(8):e67161. doi:10.7759/CUREUS.67161

130

Cortazar FB, Niles JL, Jayne DRW et al. Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan. Kidney Int Rep. 2023;8(4):860-870. doi:10.1016/j.ekir.2023.01.039

131

Geetha D, Dua A, Yue H et al. Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial. Ann Rheum Dis. 2023;83(2):223-232. doi:10.1136/ARD-2023-224816,

132

Miloslavsky EM, Naden RP, Bijlsma JWJ et al. Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. Ann Rheum Dis. 2017;76(3):543-546. doi:10.1136/ANNRHEUMDIS-2016-210002

133

Zonozi R, Aqeel F, Le D et al. Real-World Experience With Avacopan in Antineutrophil Cytoplasmic AutoantibodyAssociated Vasculitis. Kidney Int Rep. 2024;9(6):1783-1791. doi:10.1016/J.EKIR.2024.03.022,

134

Chalkia A, Flossmann O, Jones R et al. Avacopan for ANCA-associated vasculitis with hypoxic pulmonary haemorrhage. Nephrology Dialysis Transplantation. 2024;39(9):1473-1482. doi:10.1093/NDT/GFAE020,

135

Merkel PA, Niles J, Jimenez R et al. Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. ACR Open Rheumatol. 2020;2(11):662-671. doi:10.1002/ACR2.11185,

136

137

Cortazar FB, Muhsin SA, Pendergraft WF et al. Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis. Kidney Int Rep. 2018;3(2):394-402. doi:10.1016/j.ekir.2017.11.004

138

Pepper RJ, McAdoo SP, Moran SM et al. A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford). 2019;58(2):260-268. doi:10.1093/rheumatology/key288

139

Xiong A, Xiong C, Yang G et al. The Role of Mycophenolate Mofetil for the Induction of Remission in ANCAAssociated Vasculitis: A Meta-Analysis. Front Med (Lausanne). 2021;8:609924. doi:10.3389/fmed.2021.609924

140

Kuzuya K, Morita T, Kumanogoh A. Efficacy of mycophenolate mofetil as a remission induction therapy in antineutrophil cytoplasmic antibody: Associated vasculitis - A meta-analysis. RMD Open. 2020;6(1):e001195. doi:10.1136/rmdopen-2020-001195

141

Berti A, Alsawas M, Jawaid T et al. Induction and maintenance of remission with mycophenolate mofetil in ANCA-associated vasculitis: a systematic review and meta-analysis. Nephrol Dial Transplant. 2022;37(11):2190-2200. doi:10.1093/NDT/GFAB357,

142

Hu W, Liu C, Xie H et al. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephrol Dial Transplant. 2008;23(4):1307-1312. doi:10.1093/ndt/gfm780

143

Han F, Liu G, Zhang X et al. Effects of mycophenolate mofetil combined with corticosteroids for induction therapy of microscopic polyangiitis. Am J Nephrol. 2011;33(2):185-192. doi: 10.1159/000324364

144

Tuin J, Stassen PM, Bogdan DI et al. Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission in Nonlife-Threatening Relapses of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. Clinical Journal of the American Society of Nephrology. 2019;14(7):1021-1028. doi:10.2215/cjn.11801018

145

Jones RB, Hiemstra TF, Ballarin J et al. Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: A randomised, non-inferiority trial. Ann Rheum Dis. 2019;78(3):399-405. doi:10.1136/annrheumdis-2018-214245

146

Yamada Y, Harada M, Hara Y et al. Efficacy of plasma exchange for antineutrophil cytoplasmic antibody-associated systemic vasculitis: a systematic review and meta-analysis. Arthritis Res Ther. 2021;23(1):28. doi:10.1186/s13075-021-02415-z

147

Walsh M, Collister D, Zeng L et al. The effects of plasma exchange in patients with ANCA-Associated vasculitis: An updated systematic review and meta-Analysis. The BMJ. 2022;376:e064604. doi:10.1136/BMJ-2021-064604,

148

Szpirt WM, Heaf JG, Petersen J. Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener’s granulomatosisa clinical randomized controlled trial. Nephrol Dial Transplant. 2011;26(1):206-213. doi:10.1093/ndt/gfq360

149

Pusey CD, Rees AJ, Evans DJ et al. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int. 1991;40(4):757-763. doi:10.1038/ki.1991.272

150

Levy JB, Hammad T, Coulthart A et al. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int. 2004;66(4):1535-1540. doi:10.1111/j.1523-1755.2004.00917.x

151

Puéchal X, Pagnoux C, Baron G et al. Adding Azathioprine to Remission-Induction Glucocorticoids for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Microscopic Polyangiitis, or Polyarteritis Nodosa Without Poor Prognosis Factors: A Randomized, Controlled Trial. Arthritis Rheumatol. 2017;69(11):2175-2186. doi:10.1002/art.40205

152

Lionaki S, Hogan SL, Jennette CE et al. The clinical course of ANCA small-vessel vasculitis on chronic dialysis. Kidney Int. 2009;76(6):644-651. doi:10.1038/ki.2009.218

153

Geetha D, Jefferson JA. ANCA-Associated Vasculitis: Core Curriculum 2020. Am J Kidney Dis. 2020;75(1):124–137. doi:10.1053/j.ajkd.2019.04.031

154

Lee YH, Song GG. Comparative efficacy and safety of rituximab, mycophenolate, methotrexate, and cyclophosphamide versus azathioprine as maintenance therapy in antineutrophil cytoplasmic antibody-associated vasculitis: A Bayesian network metaanalysis of randomized controlled trials. Int J Clin Pharmacol Ther. 2022;60(2):97-105. doi:10.5414/CP204053

155

Charles P, Terrier B, Perrodeau É et al. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: Results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis. 2018;77(8):1144-1150. doi:10.1136/annrheumdis-2017-212878

156

Delestre F, Charles P, Karras A et al. Rituximab as maintenance therapy for ANCA-associated vasculitides: Pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials. Ann Rheum Dis. 2023;83(2):233-241. doi:10.1136/ARD-2023-224623,

157

Smith RM, Jones RB, Specks U et al. Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Ann Rheum Dis. 2020;79(9):1243-1249. doi:10.1136/annrheumdis-2019-216863

158

Pagnoux C, Mahr A, Hamidou M et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008;359:2790-2803. doi:10.1056/NEJMc090138

159

Hiemstra TF, Walsh M, Mahr A et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA. 2010;304(21):2381-2388. doi:10.1001/jama.2010.1658

160

He P, Hu JP, Tian XJ et al. Prevalence and risk factors of relapse in patients with ANCA-associated vasculitis receiving cyclophosphamide induction: a systematic review and meta-analysis of large observational studies. Rheumatology. 2021;60(3):1067-1079. doi:10.1093/rheumatology/keaa667

161

Weidanz F, Day CJ, Hewins P et al. Recurrences and infections during continuous immunosuppressive therapy after beginning dialysis in ANCA-associated vasculitis. Am J Kidney Dis. 2007;50(1):36-46. doi:10.1053/j.ajkd.2007.04.018

162

Chen M, Zhao MH. Severe pulmonary hemorrhage in patients with end-stage renal disease in antineutrophil cytoplasmic autoantibody-associated vasculitis. Am J Med Sci. 2009;337(6):411-414. doi:10.1097/MAJ.0b013e3181928d24

163

Springer J, Nutter B, Langford CA et al. Granulomatosis with polyangiitis (Wegener’s): Impact of maintenance therapy duration. Medicine (United States). 2014;93(2):82-90. doi:10.1097/MD.0000000000000020

164

Karras A, Pagnoux C, Haubitz M et al. Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Ann Rheum Dis. 2017;76(10):1662-1668. doi:10.1136/annrheumdis-2017-211123

165

Charles P, Perrodeau É, Samson M et al. Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Trial. Ann Intern Med. 2020;173(3):179-187. doi:10.7326/M19-3827

166

Walsh M, Merkel PA, Mahr A, Jayne D. Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis. Arthritis Care Res (Hoboken). 2010;62(8):1166-1173. doi:10.1002/acr.20176

167

Pagnoux C, Quéméneur T, Ninet J et al. Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: Results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. Arthritis Rheum. 2015;67(4):1117-1127. doi:10.1002/art.39011

168

169

Hellmich B, Flossmann O, Gross WL et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2007;66(5):605-617. doi:10.1136/ard.2006.062711

170

Cartin-Ceba R, Keogh KA, Specks U et al. Rituximab for the treatment of Churg-Strauss syndrome with renal involvement. Nephrology Dialysis Transplantation. 2011;26(9):2865-2871. doi:10.1093/ndt/gfq852

171

Pullerits R, Ljevak M, Vikgren J, Bokarewa M. Off-Trial Evaluation of the B cell-Targeting Treatment in the Refractory Cases of Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis: Long-Term Follow-Up from a Single Centre. Scand J Immunol. 2012;76(4):411-420. doi:10.1111/j.1365-3083.2012.02747.x

172

Miloslavsky EM, Specks U, Merkel PA et al. Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2013;65(9):2441-2449. doi:10.1002/art.38044

173

Shimizu T, Morita T, Kumanogoh A. The therapeutic efficacy of intravenous immunoglobulin in anti-neutrophilic cytoplasmic antibody-associated vasculitis: A meta-analysis. Rheumatology (United Kingdom). 2020;59(5):959-967. doi:10.1093/rheumatology/kez311

174

Fortin PM, Tejani AM, Bassett K, Musini VM. Intravenous immunoglobulin as adjuvant therapy for Wegener’s granulomatosis. Cochrane Database of Syst Rev. 2013;3:CD0070057. doi:10.1002/14651858.CD007057.pub3

175

Muso E, Ito-Ihara T, Ono T et al. Intravenous immunoglobulin (IVIg) therapy in MPO-ANCA related polyangiitis with rapidly progressive glomerulonephritis in Japan. Jpn J Infect Dis. 2004;57(5):S17-18.

176

Jayne DRW. Intravenous immunoglobulin for ANCAassociated systemic vasculitis with persistent disease activity. QJM. 2000;93(7):433-439. doi:10.1093/qjmed/93.7.433

177

O’Shaughnessy MM, Liu S, Montez-Rath ME et al. Kidney transplantation outcomes across GN subtypes in the United States. Journal of the American Society of Nephrology. 2017;28(2):632-644. doi:10.1681/ASN.2016020126

178

Geetha D, Eirin A, True K et al. Renal transplantation in antineutrophil cytoplasmic antibody-associated vasculitis: A multicenter experience. Transplantation. 2011;91(12):1370-1375. doi:10.1097/TP.0b013e31821ab9aa

179

Little MA, Hassan B, Jacques S et al. Renal transplantation in systemic vasculitis: When is it safe. Nephrol Dial Transplant. 2009;24(10):3219-3225. doi:10.1093/ndt/gfp347

180

Marco H, Mirapeix E, Arcos E et al. Long-term outcome of antineutrophil cytoplasmic antibody-associated small vessel vasculitis after renal transplantation. Clin Transplant. 2013;27(3):338-347. doi:10.1111/ctr.12084

181

Stern A, Green H, Paul M et al. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev. 2014;(10):CD005590. doi:10.1002/14651858.CD005590.pub3

182

Kronbichler A, Kerschbaum J, Gopaluni S et al. Trimethoprim-sulfamethoxazole prophylaxis prevents severe/lifethreatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2018;77(10):1440-1147. doi:10.1136/annrheumdis-2017-212861

183

Mahr A, Girard T, Agher R, Guillevin L. Analysis of factors predictive of survival based on 49 patients with systemic Wegener’s granulomatosis and prospective follow-up. Rheumatology. 2001;40(5):492-498. doi:10.1093/rheumatology/40.5.492

184

Bligny D, Mahr A, Toumelin P et al. Predicting mortality in systemic Wegener’s granulomatosis: A survival analysis based on 93 patients. Arthritis Care Res (Hoboken). 2004;51(1):83-91. doi:10.1002/art.20082

185

Kronbichler A, Jayne DRW, Mayer G. Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis. Eur J Clin Invest. 2015;45(3):346-368. doi:10.1111/eci.12410

186

Furer V, Rondaan C, Heijstek MW et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39-52. doi:10.1136/annrheumdis-2019-215882

187

Groh M, Puéchal X, Terrier B et al. Failure of pneumococcal immunization during remission induction treatment of ANCA-associated vasculitis: The Pneumovas Pilot 1 study. Joint Bone Spine. 2017;84(5):643-644. doi:10.1016/j.jbspin.2016.09.019

188

Stassen PM, Sanders JSF, Kallenberg CGM, Stegeman CA. Influenza vaccination does not result in an increase in relapses in patients with ANCA-associated vasculitis. Nephrology Dialysis Transplantation. 2008;23(2):654-658. doi:10.1093/ndt/gfm640

189

Jeffs LS, Peh CA, Jose MD et al. Randomized trial investigating the safety and efficacy of influenza vaccination in patients with antineutrophil cytoplasmic antibody-associated vasculitis. Nephrology. 2015;20(5):343-351. doi:10.1111/nep.12416

190

Reinhold-Keller E, Beuge N, Latza U et al. An interdisciplinary approach to the care of patients with Wegener’s granulomatosis: long-term outcome in 155 patients. Arthritis Rheum. 2000;43(5):1021-1032. doi:10.1002/1529-0131(200005)43:5<1021::AID-ANR10>3.0.CO;2-J

191

Fredi M, Lazzaroni MG, Tani C et al. Systemic vasculitis and pregnancy: A multicenter study on maternal and neonatal outcome of 65 prospectively followed pregnancies. Autoimmun Rev. 2015;14(8):686-691. doi:10.1016/j.autrev.2015.03.009

192

Veltri NL, Hladunewich M, Bhasin A et al. De novo antineutrophil cytoplasmic antibody-associated vasculitis in pregnancy: a systematic review on maternal, pregnancy and fetal outcomes. Clin Kidney J. 2018;11(5):659-666. doi:10.1093/ckj/sfy011

193

Leroy C, Rigot JM, Leroy M et al. Immunosuppressive drugs and fertility. Orphanet J Rare Dis. 2015;10:136. doi:10.1186/s13023-015-0332-8

194

Rüegg L, Pluma A, Hamroun S et al. EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update. Ann Rheum Dis. 2025;84(6):910-926. doi:10.1016/J.ARD.2025.02.023

195

Langford CA. Update on Wegener granulomatosis. Cleve Clin J Med. 2005;72(8):689-697. doi:10.3949/ccjm.72.8.689

196

Seo P, Min YI, Holbrook JT et al. Damage caused by Wegener’s granulomatosis and its treatment: prospective data from the Wegener’s Granulomatosis Etanercept Trial (WGET). Arthritis Rheum. 2005;52(7):2168-2178. doi:10.1002/art.21117

197

Flossmann O, Berden A, De Groot K et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis. 2011;70(3):488-494. doi:10.1136/ard.2010.137778

198

Basu N, Mcclean A, Harper L et al. Explaining fatigue in ANCA-associated vasculitis. Rheumatology (United Kingdom). 2013;52(9):1680-1685. doi:10.1093/rheumatology/ket191

199

O’Malley L, Druce K, Chanouzas D et al. The Longitudinal Course of Fatigue in Anca Associated Vasculitis. J Rheumatol. 2020;47(4):572-579. doi:10.3899/jrheum.190113

200

Basu N, Mcclean A, Harper L et al. Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis. Rheumatology (United Kingdom). 2014;53(5):953-956. doi:10.1093/rheumatology/ket483

201

Yun J Di, Ha J, Kim S et al. Predictor of depressive disorders in patients with antineutrophil cytoplasmic antibodyassociated vasculitis. Clin Rheumatol. 2019;38(12):3485-3491. doi:10.1007/s10067-019-04657-4

202

Basu N, McClean A, Harper L et al. The characterisation and determinants of quality of life in ANCA associated vasculitis. Ann Rheum Dis. 2014;73(1):207-211. doi:10.1136/annrheumdis-2012-202750

203

Herlyn K, Gross WL, Reinhold-Keller E. Longitudinal effects of structured patient education programs for vasculitis patients. Z Rheumatol. 2008;67(3):206-210. doi:10.1007/s00393-008-0290-9 (In German)

204

Pagnoux C, Hogan SL, Chin H et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum. 2008;58(9):2908-2918. doi:10.1002/art.23800

205

Lionaki S, Blyth ER, Hogan SL et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum. 2012;64(10):3452-3462. doi:10.1002/art.34562

206

Holle JU, Gross WL, Latza U et al. Improved outcome in 445 patients with Wegener’s granulomatosis in a German vasculitis center over four decades. Arthritis Rheum. 2011;63(1):257-266. doi:10.1002/art.27763

207

de Lind van Wijngaarden RAF, Hauer HA, Wolterbeek R et al. Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: A prospective analysis of 100 patients with severe renal involvement. J Am Soc Nephrol. 2006;17(8):2264-2274. doi:10.1681/ASN.2005080870

208

Mukhtyar C, Flossmann O, Hellmich B et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis. 2008;67(7):1004-1010. doi:10.1136/ard.2007.071936

209

Flossmann O, Berden A, de Groot K et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis. 2011;70(3):488-494. doi:10.1136/ard.2010.137778

210

Hogan SL, Nachman PH, Wilkman AS et al. Prognostic markers in patients with antineutrophil cytoplasmic autoantibodyassociated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol. 1996;7(1):23-32. doi: 10.1681/ASN.V7123

211

Семенкова ЕН, Кривошеев ОГ, Новиков ПИ. Поражение легких при гранулематозе Вегенера. Клиническая медицина. 2011;1:10-13.

Semenkova EN, Krivosheev OG, Novikov PI. Lung involvement in Wegener’s granulomatosis. Klinicheskaya Meditsina. 2011;1:10-13.] (In Russian)

The authors declare that there are no conflicts of interest present.